Recent Updates — BSX
Boston Scientific reported third-quarter net sales of $5.138 billion, a 1.5 percent increase on both an operational and organic basis compared to the prior year period. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, down from $755 million, or $0.51 per share, a year ago. Adjusted earnings per share came in at $0.73, compared to $0.75 in the prior-year quarter. The company also provided updated full-year 2026 guidance, estimating net sales growth of approximately 4.25 percent on a reported basis and adjusted EPS between $3.16 and $3.18. Boston Scientific operates as a global medical technology leader providing devices and therapies for cardiovascular, neuromodulation, endoscopy, urology, and other therapeutic areas.
Boston Scientific appointed Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer, effective January 1, 2027. Fitzgerald will oversee global operations, business units, and regions under a new three-segment structure: Interventional Therapies, Rhythm Solutions, and MedSurg. He receives an annual base salary of $1,050,000 and a $7 million equity grant. The company also appointed Mark Bickel as Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective March 1, 2027, succeeding Emily Woodworth. Boston Scientific develops and markets medical devices for cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.
On September 21, 2026, Arthur C. Butcher announced his retirement as Executive Vice President and Group President of MedSurg and Asia Pacific, effective January 1, 2027. He will serve as a senior advisor through February 26, 2027, receiving a prorated base salary of $780,000 annually. Upon retirement, he is entitled to benefits consistent with the Company’s Executive Retirement Plan and equity award terms. Boston Scientific Corporation operates in the medical device industry, developing and manufacturing products for interventional and specialty medical procedures.
Boston Scientific Corporation disclosed a material cybersecurity incident that began on August 25, 2026, causing global operational disruptions including network outages that impaired manufacturing capabilities and the processing of customer orders. Although unauthorized access has not been identified as ongoing and major distribution centers have resumed shipping at normal levels, the company determined the incident will likely have a material impact on its third quarter and full-year 2026 results of operations. Consequently, Boston Scientific expects to miss its previously provided net sales growth and adjusted EPS guidance ranges for these periods. The company anticipates recovering some impacted revenue as it reduces backlogs but stated that full impacts remain unknown. Boston Scientific operates in the medical device industry, developing and manufacturing products for interventional and specialty medical procedures.
Boston Scientific reported second quarter 2026 net sales of $5.442 billion, a 7.5% increase on a reported basis and 7.0% on an operational basis compared to the prior year period. GAAP net income attributable to common stockholders was $907 million, or $0.61 per share, while adjusted EPS reached $0.86, beating the guidance range of $0.82 to $0.84. The company completed a previously announced $2 billion accelerated share repurchase program, acquiring approximately 40 million shares. Additionally, Boston Scientific invested $1.5 billion in MiRus LLC for an approximate 34% equity stake and exclusive option to acquire the MiRus TAVR business. Management raised full-year 2026 adjusted EPS guidance to $3.28–$3.32 and third-quarter net sales growth guidance to 3–5%. Boston Scientific is a global medical technology company that develops, manufactures, and sells minimally invasive interventional medical devices.